Announced Date: 2025-10-21 (October 21, 2025)
Asset Name: IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC)，IBI3001 (EGFR/B7H3 ADC)
Licensor (Seller): Innovent Biologics (China)
Licensee (Buyer): Takada
.
Asset 1: IBI363 (PD-1/IL-2α-bias)
Asset Modality: bispecific antibody fusion protein
Asset Target: PD-1, IL-2
Potential Indication: several solid tumor types, including non-small cell lung and colorectal cancers
Current Stage: globally Phase 1/2 and Phase 2 clinical trials
.
IBI363 Co-develop Terms:
Takeda and Innovent will co-develop IBI363 globally with a 60/40 (Takeda/Innovent) cost split and co-commercialize it in the U.S. with a 60/40 (Takeda/Innovent) profit or loss split.
Takeda will lead co-commercialization efforts in the U.S. and will have the exclusive right to commercialize IBI363 outside of the U.S. and Greater China.
Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
.
Asset 2: IBI343 (CLDN18.2 ADC)
Asset Modality: antibody-drug conjugate (ADC)
Asset Target: Claudin 18.2 protein
Potential Indication: gastric and pancreatic cancers
Current Stage: Phase 3 clinical trial in previously treated gastric cancer in Japan and China, completed a global Phase 1/2 trial in previously treated pancreatic cancer.
Takeda will develop, manufacture and commercialize IBI343 worldwide, outside of Greater China.
.
Asset 3: IBI3001 (EGFR/B7H3 ADC)
Asset Modality: bispecific ADC
Asset Target: EGFR and B7H3
Potential Indication: solid tumors
Current Stage: Phase 1 clinical trial in patients with locally advanced or metastatic solid tumors in the U.S., China and Australia.
Takeda will receive an exclusive option to license global rights outside of Greater China for IBI3001.
Innovent will be solely responsible for clinical development of IBI3001 prior to potential exercise of the option to license.
.
.
Payment Detail:
Innovent will receive US$1.2 billion upfront payment upon closing of the transaction, which includes an equity investment of US$100 million in Innovent by Takeda. The upfront payment will be funded through cash on hand.
.
Innovent will also be eligible for potential milestones and royalty payments (up to US$10.2 billion) , and a profit or loss split 60/40 (Takeda/Innovent) solely with respect to IBI363 in the U.S., where Takeda will lead the commercialization effort while Innovent will have a co-commercialization right.
.
If Takeda exercises the option for IBI3001, Innovent will be eligible for an option exercise fee and additional potential milestone and royalty payments.
.
Link:
Takeda Announces Oncology Partnership with Innovent
.
Note:
Chinese Name of Innovent Biologics 信达生物
